Want to know:
A randomized open-label clinical trial was carried out to determine the efficacy and safety of Crizotinib (250 mg twice daily), an oral kinase inhibitor, versus standard i.v. chemotherapy (75 mg docetaxel every 3 weeks) in a cohort of patients with locally advanced or metastatic ALK-positive (anaplastic lymphoma kinase - a tyrosine kinase known to be involved in this cancer) lung cancer. The primary outcome measure was progression free survival after 24 months. Patients were recruited in multiple centres across Europe, North America and Asia based on their genotype for the alk gene.What are the main characteristics of the clinical trial phase preceding this one?
Get a detailed, AI-powered explanation for this question and thousands more on StudyFetch.
Get the Answer for FreeHow StudyFetch Helps You Master This Topic
AI-Powered Answers
Get instant, detailed explanations powered by AI that understands your course material.
Deep Understanding
Go beyond surface-level answers with step-by-step breakdowns and examples.
Personalized Learning
Spark.E adapts to your learning style and helps you connect ideas.
Practice & Test
Turn any question into flashcards, quizzes, and practice tests to solidify your knowledge.